The growth in the quarter included increased sales-related travel and medical education, which were largely curtailed last year as we emerged from restrictions on in-person activities.

Nov 8, 2022 / receipt, needs a key / Cheryl, other | earnings call 2022-11-08 | transcript 3e637722-d30a-4364-b4b1-9785c984340d | chars 23017-23201 | segment 23

The growth in the quarter included increased sales-related travel and medical education, which were largely curtailed last year, as we emerged from restrictions on in-person activities.

Aug 3, 2022 / receipt, needs a key / Mike Levitz, CFO | earnings call 2022-08-03 | transcript 3a7e8b4e-ae21-4fb3-9833-052d1eec0aa8 | chars 13378-13563 | segment 13

On the current quarter, SG&A looks like it's up by about 2 million. Is that because of the increased travel or the increased stock-based compensation or a combination of both?

Aug 3, 2022 / receipt, needs a key / Jim Sidoti, other | earnings call 2022-08-03 | transcript 3a7e8b4e-ae21-4fb3-9833-052d1eec0aa8 | chars 19407-19582 | segment 19

Hi, Jim. It's Mike. It's a combination of both of those things. As I mentioned, we're now seeing the medical education spending coming in, the travels picking up now that we can resume in-person meetings, which is great news.

Aug 3, 2022 / receipt, needs a key / Mike Levitz, CFO | earnings call 2022-08-03 | transcript 3a7e8b4e-ae21-4fb3-9833-052d1eec0aa8 | chars 19583-19808 | segment 19

We do expect that to increase through the year because we suspended a lot of the marketing efforts last year with COVID trade shows and the like. And so as things open up, we do expect those, those costs to increase.

Mar 4, 2021 / receipt, needs a key / Jim, CEO | earnings call 2021-03-04 | transcript bb86d786-5737-467e-88f4-e8ecbee22fee | chars 37385-37601 | segment 37

Selling, General and Administrative $21.5M $27.0M ($5.5)M

ir_statement / Sep 17, 2026 / receipt

2024 FULL YEAR GUIDANCE - UNCHANGED

ir_statement / Sep 17, 2026 / receipt

Global headcount to reduce from ~325 to ~225

ir_statement / Sep 17, 2026 / receipt

Optimized to drive strategic focus on profitable, core HA technology, and advance differentiated and growing Regenerative Solutions portfolio

ir_statement / Sep 17, 2026 / receipt

Rightsizing to Dedicate Resources on Development, Manufacturing, Sales and Marketing of our HA-products

ir_statement / Sep 17, 2026 / receipt

On track to deliver $10M annualized cost savings

ir_statement / Sep 17, 2026 / receipt

Commercial Channel $41 to $43M +14% to +19%

ir_statement / Sep 17, 2026 / receipt

Commercial Channel +18% CAGR 2021-2023; expect +16% in 2024 (at mid-point of guidance)

ir_statement / Sep 17, 2026 / receipt

OEM Channel $76 to $78M (8%) to (10%)

ir_statement / Sep 17, 2026 / receipt

Total Revenue $117 to $121M

ir_statement / Sep 17, 2026 / receipt

International OA Pain revenue grew 17% year-to-date across Cingal®, Monovisc® and Orthovisc® on market share gains and new country expansion

ir_statement / Sep 17, 2026 / receipt

Realizing operating expense savings resulting in 73% growth in adjusted EBITDA year-to-date

ir_statement / Sep 17, 2026 / receipt